Equities researchers at Zacks Research lifted their Q4 2024 earnings estimates for Sarepta Therapeutics in a research note issued to investors on Monday, February 3rd. Zacks Research analyst S.

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article ...

RBC Capital analyst Brian Abrahams says shares of Sarepta (SRPT) could be trading lower today on an FDA database update that ...

Sarepta Therapeutics (NASDAQ:SRPT), a biotechnology company specializing in precision genetic medicines for rare diseases with a market capitalization of $11.2 billion, stands at a critical juncture ...

Sarepta's EMBARK study confirms Elevidys offers sustained Duchenne treatment benefits, including motor function improvement ...

Nisa Investment Advisors LLC grew its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 23.1% ...

Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Sell rating on Sarepta Therapeutics (SRPT – Research Report). The associated ...

Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Buy rating on Sarepta Therapeutics (SRPT – Research Report). The ...

We recently published an article titled Jim Cramer’s Lightning Rounds: 9 Stocks in Focus. In this article, we are going to ...

Sarepta's third-quarter results for 2024 exceeded expectations, with total revenue reaching approximately $430 million, surpassing the consensus estimate of $400 million. The company's trailing ...

Roche and Sarepta Therapeutics have shared positive top-line results from a late-stage study of Elevidys (delandistrogene ...